Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Intervalo de año de publicación
1.
Microorganisms ; 10(3)2022 Feb 26.
Artículo en Inglés | MEDLINE | ID: mdl-35336089

RESUMEN

Combination therapy has, to some extent, been successful in limiting the emergence of drug-resistant tuberculosis. Drug combinations achieve this advantage by simultaneously acting on different targets and metabolic pathways. Additionally, drug combination therapies are shown to shorten the duration of therapy for tuberculosis. As new drugs are being developed, to overcome the challenge of finding new and effective drug combinations, systems biology commonly uses approaches that analyse mycobacterial cellular processes. These approaches identify the regulatory networks, metabolic pathways, and signaling programs associated with M. tuberculosis infection and survival. Different preclinical models that assess anti-tuberculosis drug activity are available, but the combination of models that is most predictive of clinical treatment efficacy remains unclear. In this structured literature review, we appraise the options to accelerate the TB drug development pipeline through the evaluation of preclinical testing assays of drug combinations.

2.
Ann Hepatol ; 17(2): 286-299, 2018 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-29469045

RESUMEN

INTRODUCTION: Adiponectin and resistin levels are increased in patients with cirrhosis, but it prognostic significance is unknown. We sought to investigate the factors associated with adiponectin and resistin levels and its clinical significance in patients with cirrhosis. MATERIALS AND METHODS: This was a prospective cohort study that included 122 subjects with cirrhosis who attended an outpatient clinic and were initially evaluated in 2012. Serum adiponectin and resistin levels were measured in samples collected in 2012 (adiponectin and resistin) and 2014 (adiponectin). Thirty healthy subjects served as a control group. RESULTS: Higher adiponectin (21.59 µ g/mL vs. 12.52 µg/mL, P < 0.001) and resistin levels (3.83 ng/mL vs. 2.66 ng/mL, P < 0.001) were observed among patients with cirrhosis compared to controls. Patients classified as Child-Pugh B/C had higher adiponectin levels in relation to Child-Pugh A patients. At second measurement, adiponectin levels increased significantly in non-transplant patients and decreased in liver transplant recipients. Univariate Cox analysis showed that among patients with alcoholic liver disease, adiponectin levels were associated with lower transplant-free survival (HR = 1.034, 95% CI 1.006 - 1.062, P = 0.016). The transplant-free survival was significantly lower among patients with alcoholic liver disease and adiponectin ≥ 17 µg/mL (26.55 months, 95% CI 21.40-31.70) as compared to those with levels < 17 µg/mL (33.76 months, 95% CI 30.70-36.82) (P = 0.045). No relationship was found between the levels of resistin and survival. CONCLUSION: Adiponectin but not resistin levels were associated with intensity of liver dysfunction and worse prognosis in patients with alcoholic liver disease, suggesting a potential as a prognostic biomarker.


Asunto(s)
Adiponectina/sangre , Cirrosis Hepática/sangre , Resistina/sangre , Adulto , Anciano , Biomarcadores/sangre , Estudios de Casos y Controles , Femenino , Estado de Salud , Humanos , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/cirugía , Cirrosis Hepática Alcohólica/sangre , Cirrosis Hepática Alcohólica/diagnóstico , Cirrosis Hepática Alcohólica/cirugía , Trasplante de Hígado , Masculino , Persona de Mediana Edad , Supervivencia sin Progresión , Estudios Prospectivos , Factores de Tiempo , Regulación hacia Arriba
3.
Ann Hepatol ; 16(5): 780-787, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28809733

RESUMEN

BACKGROUND: Despite the circulating levels of PTX3 were related to the severity of various diseases, there are no studies investigating its role in patients with liver cirrhosis. We aimed to study PTX3 levels in patients with liver cirrhosis. MATERIAL AND METHODS: A prospective cohort study included 130 patients hospitalized for acute decompensation of liver cirrhosis, 29 stable cirrhotic outpatients and 32 healthy controls evaluated in a tertiary hospital in Southern Brasil. RESULTS: The median PTX3 level was significantly higher in stable cirrhotic patients compared to controls (2.6 vs. 1.1 ng/mL; p < 0.001), hospitalized cirrhotic patients compared to controls (3.8 vs. 1.1 ng/mL; p < 0.001), and hospitalized cirrhotic patients compared to stable cirrhotic patients (3.8 vs. 2.6 ng/mL; p = 0.001). A positive correlation was found between PTX3 and serum creatinine (r = 0.220; p = 0.012), Chronic Liver Failure - Sequential Organ Failure Assessment score (CLIF-SOFA) (r = 0.220; p = 0.010), MELD (r = 0.279; p = 0.001) and Child-Pugh score (r = 0.224; p = 0.010). Significantly higher levels of PTX3 were observed in patients on admission with ACLF (8.9 vs. 3.1 ng/mL; p < 0.001) and MELD score ≥ 20 (6.6 vs. 3.4 ng/mL; p = 0.002). Death within 90 days occurred in 30.8% of patients and was associated with higher levels of PTX3 (5.3 vs. 3.4 ng/mL; p = 0.009). The probability of Kaplan-Meier survival was 77.0% in patients with PTX-3 < 5.3 ng mL (upper tercile) and 53.5% in those with PTX3 ≥ 5.3 ng/mL (p = 0.002). CONCLUSION: These results indicate the potential for use of PTX3 as an inflammatory biomarker for the prognosis of patients with hepatic cirrhosis.


Asunto(s)
Proteína C-Reactiva/análisis , Mediadores de Inflamación/sangre , Cirrosis Hepática/sangre , Componente Amiloide P Sérico/análisis , Insuficiencia Hepática Crónica Agudizada/sangre , Insuficiencia Hepática Crónica Agudizada/diagnóstico , Insuficiencia Hepática Crónica Agudizada/mortalidad , Adulto , Biomarcadores/sangre , Brasil , Estudios de Casos y Controles , Creatinina/sangre , Femenino , Hospitalización , Humanos , Estimación de Kaplan-Meier , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/mortalidad , Masculino , Persona de Mediana Edad , Puntuaciones en la Disfunción de Órganos , Pronóstico , Estudios Prospectivos , Factores de Riesgo , Centros de Atención Terciaria , Factores de Tiempo
4.
Salud(i)ciencia (Impresa) ; 20(7): 698-701, Ago.2014. tab
Artículo en Portugués | LILACS | ID: lil-796496

RESUMEN

Reação em Cadeia da (La reacción en cadena de la) Polimerase Multiplex (PCR- multiplex) é um (es un) método diagnostico potencialmente útil para identificação rápida e acurada (y exacta) de Mycobacterium tuberculosis (TB) e de micobactérias não-tuberculosas (MNT) clinicamente relevantes. Este sistema multi-iniciadores (multiprimers) é capaz de identificar o (el) antígeno alfa de 32-kDa presente na (en la) maioria das (de las) espécies do gênero Mycobacterium, a sequência de inserção IS6110 pertencente ao complexo (al complejo) TB e as sequências espécie-específicas do (del) gene mtp 40 de Mycobacterium tuberculosis. Cento e oito a mostras (Ciento ocho muestras) (escarro [esputo] e extra-pulmonares) oriundas do Setor de Tuberculose do Laboratório Central de Saúde Pública de Santa Catarina (LACEN/SC) foram processadas e analisadas no Laboratório de Biologia Molecular e Micobactérias (LBMM) da Universidade Federal de Santa Catarina, Florianópolis, Brasil, entre janeiro e junho de 2011, representando 30% dasa mostras (de las muestras) positivas/ano no (al año en el) LACEN/SC. Dos (Entre los) 108 isolados (aislamientos), 80% foram identificados como TB e 20% como MNT. Os resultados da PCR multiplex foram comparados com os resultados do PRA-hsp65 (PCR do gene hsp65 seguida por análise de restrição enzimática) e demonstraram 100% de concordancia (índice de concordância kappa 1). A PCR multiplex é uma ferramenta (es una herramienta)...


Asunto(s)
Humanos , Mycobacterium , Tuberculosis , Biología Molecular , Brasil , Reacción en Cadena de la Polimerasa
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...